Sarepta Therapeutics
SRPT
#4367
Rank
HK$18.61 B
Marketcap
HK$177.61
Share price
4.49%
Change (1 day)
-81.97%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

Operating Margin for Sarepta Therapeutics (SRPT)

Operating Margin as of December 2025 (TTM): -10.44%

According to Sarepta Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -10.44%. At the end of 2024 the company had an Operating Margin of 14.68%.

Operating Margin history for Sarepta Therapeutics from 2001 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
202414.68%-136.64%
2023-40.06%-41.3%
2022-68.24%34.77%
2021-50.64%-44.54%
2020-91.30%-49.11%
2019-179.40%64.2%
2018-109.26%294.36%
2017-27.70%-99.43%
2016-4,895.28%-71.95%
2015-17,451.32%1172.69%
2014-1,371.21%115.95%
2013-634.95%697.97%
2012-79.57%4.07%
2011-76.46%7.45%
2010-71.16%-19.31%
2009-88.18%6.86%
2008-82.52%-72.62%
2007-301.38%-98.95%
2006-28,608.52%7713.06%
2005-366.16%-93.71%
2004-5,817.95%198.97%
2003-1,945.99%-35.74%
2002-3,028.39%38.83%
2001-2,181.36%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Gilead Sciences
GILD
33.98%-425.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
-25.89% 147.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Avidity Biosciences
RNA
-2,634.59% 25,135.54%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
-1.10%-89.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
-16.78% 60.73%๐Ÿ‡บ๐Ÿ‡ธ USA
PTC Therapeutics
PTCT
41.64%-498.85%๐Ÿ‡บ๐Ÿ‡ธ USA
Insmed
INSM
-250.21% 2,296.65%๐Ÿ‡บ๐Ÿ‡ธ USA

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.